- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 401/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
Patent holdings for IPC class C07D 401/08
Total number of patents in this class: 251
10-year publication summary
|
10
|
18
|
20
|
32
|
16
|
24
|
12
|
26
|
10
|
2
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Nxera Pharma UK Limited | 119 |
14 |
| Assembly Biosciences, Inc. | 68 |
10 |
| Pfizer Inc. | 3363 |
9 |
| Heptares Therapeutics Limited | 118 |
8 |
| Bristol-myers Squibb Company | 4865 |
7 |
| Merck Patent GmbH | 5848 |
7 |
| Janssen Pharmaceutica N.V. | 3611 |
6 |
| Merck Sharp & Dohme LLC | 3752 |
6 |
| F. Hoffmann-La Roche AG | 7951 |
5 |
| AstraZeneca AB | 2968 |
5 |
| Incyte Holdings Corporation | 653 |
5 |
| Karyopharm Therapeutics Inc. | 141 |
5 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 806 |
5 |
| Cytokinetics, Inc. | 268 |
4 |
| Incyte Corporation | 967 |
4 |
| Taro Pharmaceuticals Inc. | 40 |
4 |
| Universite de Rouen | 105 |
4 |
| Incyte Holdings Corporation and Incyte Corporation | 89 |
4 |
| Syngenta Participations AG | 3030 |
3 |
| Vertex Pharmaceuticals Incorporated | 1568 |
3 |
| Other owners | 133 |